Heather Richardson
Family · Joplin, MONPI 1851052427
Payments from drug & device makers
Across 320 payments — averaging $14.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$627
- AstraZeneca$594
- Novo Nordisk$528
- Lilly USA, LLC$356
- Otsuka America Pharmaceutical, Inc.$320
- GSK$269
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,778100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 65 | $627 |
| AstraZeneca | 31 | $594 |
| Novo Nordisk | 32 | $528 |
| Lilly USA, LLC | 24 | $356 |
| Otsuka America Pharmaceutical, Inc. | 20 | $320 |
| GSK | 21 | $269 |
| Pfizer | 12 | $186 |
| Amgen | 11 | $185 |
| Novartis | 11 | $178 |
| Merck | 11 | $172 |
| Johnson & Johnson | 9 | $132 |
| Boehringer Ingelheim | 7 | $109 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $108 |
| Dexcom, Inc. | 5 | $80 |
| Axsome Therapeutics, Inc. | 5 | $79 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $75 |
| Abbott | 3 | $71 |
| Bayer | 4 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $69 |
| Exact Sciences | 4 | $66 |
| Verona Pharma, Inc. | 4 | $58 |
| Dynavax Technologies Corporation | 3 | $56 |
| Ironwood Pharmaceuticals, Inc | 3 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $43 |
| Vertex | 2 | $38 |
| Nestle Healthcare Nutrition Inc. | 2 | $35 |
| Sanofi | 1 | $31 |
| Boston Scientific | 1 | $29 |
| Neurelis, Inc. | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Viatris Specialty LLC | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Organon | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
| Shield Therapeutics Inc | 1 | $13 |
How this compares
$4,798 in reported general payments places this provider in the 90th percentile of 3,812 family providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 95 | $125,911 |
| OzempicSemaglutide | 61 | $89,457 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $54,432 |
| VraylarCariprazine Hcl | 33 | $53,778 |
| TrulicityDulaglutide | 34 | $41,955 |
| RexultiBrexpiprazole | 29 | $39,290 |
| EliquisApixaban | 26 | $37,346 |
| MounjaroTirzepatide | 32 | $35,469 |
| FarxigaDapagliflozin Propanediol | 24 | $23,530 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $8,644 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 137 | $3,690 |
| Gabapentin | 157 | $2,263 |
| Tizanidine Hcl | 35 | $1,773 |
| Fluticasone Propionate | 62 | $1,132 |
| Ventolin HfaAlbuterol Sulfate | 16 | $983 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $109 | $125,91195 claims |
| Novo NordiskOzempic | $528 | $89,45761 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $356 | $77,42466 claims |
| GSKTrelegy Ellipta | $269 | $54,43261 claims |
| AbbVieVraylar | $627 | $53,77833 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $320 | $39,29029 claims |
| PfizerEliquis | $186 | $37,34626 claims |
| AstraZenecaFarxiga, Symbicort | $594 | $32,17456 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,812 family providers in Missouri.
Other family in Joplin
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Laura HedigerSpringfield$71K
- Rebecca SeabaughSaint Louis$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.